Announcements Trials
Browse Landscape

Phase

Phase 2 55Phase 3 8Phase 4 5Phase 2/3 3Phase 1 3Phase NA 2Phase 1/2 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Quality of Life 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × endostar protein × Clear all
NCT01907529 2019-08-09

TENDENCY

Hebei Medical University Fourth Hospital

Phase 2/3 Unknown
300 enrolled
Breast

Breast Neoplasms

NCT03588494 2018-07-17

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Affiliated Hospital of North Sichuan Medical College

Phase 2/3 Unknown
318 enrolled

Quality of Life

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Peking University Third Hospital

Phase 2/3 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡